Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMUQ0E8)

Drug Name
Tepotinib Drug Info
Synonyms
1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo
Cross-matching ID
PubChem CID
25171648
ChEBI ID
CHEMBL3402762
CAS Number
CAS 1100598-32-0
TTD Drug ID
D0R8QG

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Steroid biosynthesis 2.46 0.00e+0 19/20 (95%) MSMO1;SQLE;DHCR7;...
Biosynthesis of unsaturated fatty acids 2.27 0.00e+0 21/27 (77.78%) SCD;ELOVL6;FADS1;...
Terpenoid backbone biosynthesis 2.02 0.00e+0 18/22 (81.82%) ACAT2;HMGCS1;FDPS;...
Valine, leucine and isoleucine degradation 1.96 6.47e-3 42/48 (87.5%) ACAT2;HMGCS1;BCAT1;...
Renin secretion 1.88 8.62e-3 61/69 (88.41%) GNAS;PLCB4;CACNA1D;...
Fatty acid biosynthesis 1.86 8.62e-3 16/18 (88.89%) FASN;ACSL1;ACACA;...
Butanoate metabolism 1.83 1.11e-2 23/28 (82.14%) ACAT2;HMGCS1;AACS;...
Retinol metabolism 1.82 1.08e-2 41/68 (60.29%) CYP3A5;RDH11;CYP2C18;...
Steroid hormone biosynthesis 1.81 9.58e-3 43/61 (70.49%) CYP3A5;HSD17B7;CYP1B1;...
Phosphatidylinositol signaling system 1.81 8.62e-3 82/97 (84.54%) PLCB4;ITPR2;PLCB1;...
Synthesis and degradation of ketone bodies 1.78 1.10e-2 9/10 (90%) ACAT2;HMGCS1;BDH2
Sulfur metabolism 1.76 1.44e-2 9/10 (90%) PAPSS2;SUOX;ETHE1
Fatty acid degradation 1.75 1.33e-2 40/43 (93.02%) ACAT2;ACSL1;ACSL3;...
Propanoate metabolism 1.72 1.79e-2 30/34 (88.24%) ACAT2;ACACA;ACOX3;...
Glycerophospholipid metabolism 1.71 1.90e-2 71/98 (72.45%) LPIN1;ETNK1;PLA2G2A;...
ABC transporters 1.70 2.05e-2 37/45 (82.22%) ABCA5;ABCC5;ABCC1;...
Pyruvate metabolism 1.70 1.93e-2 41/47 (87.23%) ACAT2;ACACA;ME1;...
Selenocompound metabolism 1.66 2.78e-2 11/17 (64.71%) PAPSS2;SEPHS2;SEPHS1;...
PPAR signaling pathway 1.64 3.36e-2 66/74 (89.19%) SCD;HMGCS1;ACSL1;...
Vibrio cholerae infection 1.64 3.19e-2 44/50 (88%) GNAS;SLC12A2;TJP2;...
RNA polymerase -1.68 4.45e-2 23/31 (74.19%) POLR2J;POLR2E;POLR3D;...
RNA degradation -1.69 4.75e-2 53/79 (67.09%) TOB1;EXOSC8;LSM4;...
Cell adhesion molecules -1.69 4.88e-2 118/148 (79.73%) HLA-A;NLGN1;NRCAM;...
Asthma -1.73 4.52e-2 25/31 (80.65%) CD40LG;FCER1G;HLA-DPB1;...
Mineral absorption -1.73 4.94e-2 48/60 (80%) CYBRD1;ATP1B2;FTL;...
NF-kappa B signaling pathway -1.77 3.98e-2 90/104 (86.54%) LCK;DDX58;MALT1;...
Chemokine signaling pathway -1.79 4.45e-2 163/192 (84.9%) CCL11;PIK3CA;GNB2;...
Ribosome -1.81 3.95e-2 113/158 (71.52%) RPL17;MRPL13;RPS23;...
Rheumatoid arthritis -1.97 0.00e+0 78/93 (83.87%) IL6;JUN;ATP6V0B;...
Viral protein interaction with cytokine and cytokine re... -1.98 0.00e+0 84/100 (84%) CCL11;IL2RG;CX3CL1;...
Intestinal immune network for IgA production -1.98 0.00e+0 38/48 (79.17%) CD28;TNFRSF13B;CD40LG;...
IL-17 signaling pathway -2.24 0.00e+0 84/94 (89.36%) IL17RB;IL17RC;IL6;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Ewing sarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
SK-ES-1 CVCL_0627 Homo sapiens 1.11uM - 10uM 24H
Brain
Glioma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
GI-1 CVCL_1230 Homo sapiens 1.11uM - 10uM 24H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.01uM - 10uM 24H
MDA-MB-231 CVCL_0062 Homo sapiens 0.03uM - 10uM 24H
MDA-MB-468 CVCL_0419 Homo sapiens 1.11uM - 10uM 24H
Breast ductal carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
T-47D CVCL_0553 Homo sapiens 1.11uM - 10uM 24H
Breast epithelium
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF-10A CVCL_0598 Homo sapiens 0.01uM - 10uM 24H
Cervix
Cervical adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HeLa CVCL_0030 Homo sapiens 0.01uM - 10uM 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 0.01uM - 10uM 24H
SNU-407 CVCL_5004 Homo sapiens 1.11uM - 10uM 24H
Endometrium
Endometrial adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEC-108 CVCL_2926 Homo sapiens 1.11uM - 10uM 24H
HEC-1-A CVCL_0293 Homo sapiens 1.11uM - 10uM 24H
HEC-251 CVCL_2928 Homo sapiens 1.11uM - 3.33uM 24H
HEC-265 CVCL_2929 Homo sapiens 1.11uM - 10uM 24H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
CJM CVCL_U797 Homo sapiens 1.11uM - 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.01uM - 10uM 24H
Normal (Transformed)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEK293 CVCL_0045 Homo sapiens 0.01uM - 10uM 24H
Liver
Hepatocellular carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
JHH-5 CVCL_1320 Homo sapiens 1.11uM - 10uM 24H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.01uM - 10uM 24H
NCI-H1573 CVCL_1483 Homo sapiens 1.11uM - 10uM 24H
NCI-H838 CVCL_1594 Homo sapiens 1.11uM - 10uM 24H
Lung squamous cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
BEN CVCL_1081 Homo sapiens 1.11uM - 10uM 24H
HCC95 CVCL_1276 Homo sapiens 1.11uM - 10uM 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NCI-H2110 CVCL_1529 Homo sapiens 1.11uM - 10uM 24H
Muscle
Rhabdomyosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-204 CVCL_0134 Homo sapiens 1.11uM - 10uM 24H
Ovary
Ovarian clear cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
OVTOKO CVCL_3114 Homo sapiens 1.11uM - 10uM 24H
Pancreas
Pancreatic carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
YAPC CVCL_1791 Homo sapiens 0.01uM - 10uM 24H
Peripheral blood
Acute monocytic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
THP-1 CVCL_0006 Homo sapiens 0.01uM - 10uM 24H
T-cell acute lymphoblastic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Jurkat CVCL_0367 Homo sapiens 0.01uM - 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
22Rv1 CVCL_1045 Homo sapiens 3.33uM - 10uM 24H
PC-3 CVCL_0035 Homo sapiens 0.01uM - 10uM 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.01uM - 10uM 24H
IGR-37 CVCL_1303 Homo sapiens 1.11uM - 10uM 24H
Mel-HO CVCL_1402 Homo sapiens 1.11uM - 10uM 24H
SH-4 CVCL_1692 Homo sapiens 1.11uM - 10uM 24H
Urinary bladder
Bladder carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
BC-3C CVCL_1079 Homo sapiens 1.11uM - 10uM 24H
Bladder transitional cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
CAL-29 CVCL_1109 Homo sapiens 1.11uM - 10uM 24H